https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00altusdevsite_4grsdfhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgaltusdevsite_4grsdf2018-07-16 19:58:222020-05-05 19:55:00Press Release: Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin
Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200 June 11, 2018 07:58 AM Eastern Daylight Time FAIRFAX, Va.–(EON: Enhanced Online News)–Vizuri Health Sciences LLC, a pharmaceutical and over-the-counter (OTC) product development company, today announced the initiation of clinical study VZU00025: A Phase […]
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00altusdevsite_4grsdfhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgaltusdevsite_4grsdf2018-06-11 07:58:232020-05-05 19:55:08Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200
Press Release: Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin
/in all, press release /by altusdevsite_4grsdfVizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin
Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200
/1 Comment/in all, press release /by altusdevsite_4grsdfPress Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200 June 11, 2018 07:58 AM Eastern Daylight Time FAIRFAX, Va.–(EON: Enhanced Online News)–Vizuri Health Sciences LLC, a pharmaceutical and over-the-counter (OTC) product development company, today announced the initiation of clinical study VZU00025: A Phase […]